Literature DB >> 7538635

Treatment of intracranial nongerminomatous malignant germ cell tumors producing alpha-fetoprotein.

Y Itoyama1, M Kochi, J Kuratsu, S Takamura, I Kitano, T Marubayashi, S Uemura, Y Ushio.   

Abstract

We treated 10 patients with intracranial nongerminomatous malignant germ cell tumors producing alpha-fetoprotein between 1969 and 1992. Two patients were treated with radiotherapy (RT) only (RT group), and three were treated with RT and cisplatin plus vinblastine plus bleomycin therapy with or without surgery (cisplatin plus vinblastine plus bleomycin group). The most recently treated five patients received cisplatin plus etoposide (PE) therapy with or without RT and/or surgery (PE group). The level of alpha-fetoprotein in serum was elevated in all 10 patients. In the PE group, PE therapy consisted of cisplatin (20 mg/m2) and etoposide (60 mg/m2) daily for 5 days (one course) given two or three times at 4-week intervals and then once every 4 months; the patients received three to six courses (mean, 4.2 courses). In the RT group (n = 2), one patient died 3 months after diagnosis and the other died at 12 months. In the cisplatin plus vinblastine plus bleomycin group (n = 3), complete remission was obtained in one patient, but the other two patients died 12 and 24 months after diagnosis. In contrast, in the PE group (n = 5), complete remission was obtained in all patients who are all currently alive without recurrence, at 35 to 71 months (average, 53.6 mo) after diagnosis. The results indicate that multidisciplinary treatment including combination chemotherapy with cisplatin and etoposide with or without surgery and/or RT is highly effective in the treatment of patients with alpha-fetoprotein-producing intracranial nongerminomatous malignant germ cell tumor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538635     DOI: 10.1227/00006123-199503000-00003

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Multimodality therapy for CNS mixed malignant germ cell tumors (MMGCT): results of a phase II multi-institutional study.

Authors:  Patricia L Robertson; Regina Jakacki; Juliette Hukin; Joao Siffert; Jeffrey C Allen
Journal:  J Neurooncol       Date:  2014-04-04       Impact factor: 4.130

2.  Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children's Oncology Group.

Authors:  C Kretschmar; L Kleinberg; M Greenberg; P Burger; Emi Holmes; M Wharam
Journal:  Pediatr Blood Cancer       Date:  2007-03       Impact factor: 3.167

3.  Improved outcome of central nervous system germ cell tumors: implications for the role of risk-adapted intensive chemotherapy.

Authors:  Keon Hee Yoo; Soo Hyun Lee; Jeehun Lee; Ki Woong Sung; Hye Lim Jung; Hong Hoe Koo; Do Hoon Lim; Jong Hyun Kim; Hyung Jin Shin
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

4.  Modified grading system for clinical outcome of intracranial non-germinomatous malignant germ cell tumors.

Authors:  Xiang Huang; Rong Zhang; Ying Mao; Liang-Fu Zhou
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

5.  Endoscopic options in management of posterior third ventricular tumors.

Authors:  S V Roopesh Kumar; Aaron Mohanty; Vani Santosh; Satyanarayana Satish; B Indira Devi; Shanti Shankar Praharaj; Sastry V R Kolluri
Journal:  Childs Nerv Syst       Date:  2007-05-31       Impact factor: 1.475

Review 6.  Pineal germ cell tumors: Two cases with review of histopathologies and biomarkers.

Authors:  Daniel T Nagasawa; Carlito Lagman; Michael Sun; Andrew Yew; Lawrance K Chung; Seung J Lee; Timothy T Bui; Yinn Cher Ooi; R Aaron Robison; Gabriel Zada; Isaac Yang
Journal:  J Clin Neurosci       Date:  2017-02-08       Impact factor: 1.961

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.